These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? Macdonald D; Cuthbertson L; Doherty C; Campana S; Ravenni N; Taccetti G; Govan JR J Antimicrob Chemother; 2010 Nov; 65(11):2373-5. PubMed ID: 20837573 [TBL] [Abstract][Full Text] [Related]
5. Genetic relatedness of Pseudomonas aeruginosa isolates among a paediatric cystic fibrosis patient cohort in Ireland. Logan C; Habington A; Lennon G; Grogan J; Byrne M; O'Leary J; O'Sullivan N J Med Microbiol; 2012 Jan; 61(Pt 1):64-70. PubMed ID: 21921114 [TBL] [Abstract][Full Text] [Related]
6. [Discrepancy in the disk diffusion susceptibility test of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients after anaerobic preincubation and its potential clinical relevance]. Cafini F; García-Rey C; Bas P; Gómez-Lus ML; Sánchez I; Vázquez S; Prieto J Rev Esp Quimioter; 2012 Dec; 25(4):269-73. PubMed ID: 23303259 [TBL] [Abstract][Full Text] [Related]
7. [Antimicrobial susceptibility in Pseudomonas aeruginosa strains taken from patients with cystic fibrosis]. Pérez Monrás MF; Batlle Almodóvar Mdel C; Verdera Hernández J; Hernández AL Rev Cubana Med Trop; 2006; 58(3):207-11. PubMed ID: 23424788 [TBL] [Abstract][Full Text] [Related]
8. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment. Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333 [TBL] [Abstract][Full Text] [Related]
9. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy. Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098 [TBL] [Abstract][Full Text] [Related]
10. Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)--a cause for concern? Ashish A; Shaw M; Winstanley C; Ledson MJ; Walshaw MJ J Cyst Fibros; 2012 May; 11(3):173-9. PubMed ID: 22146482 [TBL] [Abstract][Full Text] [Related]
11. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Sajjan US; Tran LT; Sole N; Rovaldi C; Akiyama A; Friden PM; Forstner JF; Rothstein DM Antimicrob Agents Chemother; 2001 Dec; 45(12):3437-44. PubMed ID: 11709321 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria. Strateva T; Petrova G; Mitov I J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744 [TBL] [Abstract][Full Text] [Related]
13. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Burns JL; Saiman L; Whittier S; Larone D; Krzewinski J; Liu Z; Marshall SA; Jones RN J Clin Microbiol; 2000 May; 38(5):1818-22. PubMed ID: 10790106 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria. Petrova G; Strateva T; Miteva D; Lazova S; Perenovska P J Infect Dev Ctries; 2016 Nov; 10(11):1265-1267. PubMed ID: 27886041 [TBL] [Abstract][Full Text] [Related]
15. Comparison of susceptibility of cystic-fibrosis-related and non-cystic-fibrosis-related Pseudomonas aeruginosa to chlorine-based disinfecting solutions: implications for infection prevention and ward disinfection. Moore JE; Rendall JC J Med Microbiol; 2014 Sep; 63(Pt 9):1214-1219. PubMed ID: 24925907 [TBL] [Abstract][Full Text] [Related]
16. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Ciofu O; Riis B; Pressler T; Poulsen HE; Høiby N Antimicrob Agents Chemother; 2005 Jun; 49(6):2276-82. PubMed ID: 15917521 [TBL] [Abstract][Full Text] [Related]
17. Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis. Lim SZP; Fitzgerald DA Paediatr Respir Rev; 2018 Jun; 27():33-36. PubMed ID: 29033215 [TBL] [Abstract][Full Text] [Related]
18. Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Li Y; Zhang X; Wang C; Hu Y; Niu X; Pei D; He Z; Bi Y Mol Med Rep; 2015 Jan; 11(1):494-8. PubMed ID: 25323940 [TBL] [Abstract][Full Text] [Related]
19. Mixed morphotype testing of Pseudomonas aeruginosa cultures from cystic fibrosis patients. Wolter JM; Kotsiou G; McCormack JG J Med Microbiol; 1995 Mar; 42(3):220-4. PubMed ID: 7884805 [TBL] [Abstract][Full Text] [Related]
20. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Cheng K; Smyth RL; Govan JR; Doherty C; Winstanley C; Denning N; Heaf DP; van Saene H; Hart CA Lancet; 1996 Sep; 348(9028):639-42. PubMed ID: 8782753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]